Scoop has an Ethical Paywall
Pfizer Response To Pharmac Statement
Thursday 23 December 2004
Pfizer Response To Pharmac Statement
Pfizer New Zealand rejects PHARMAC’s statement in its entirety.
It is factually incorrect to say that Pfizer NZ is promoting the cardiovascular safety of Celebrex following “reports” pointing to potential problems.
One clinical trial - in cancer patients using doses of 400-800mg/day- showed a signal for possible cardiovascular side effects, while a similar trial did not.
Pfizer took the responsible step of proactively putting that information in the public domain as soon as it became known on 17th December.
PHARMAC’s implication that there were known cardiovascular safety problems with Celebrex prior to 17th December is simply not true.
Pfizer has halted direct to consumer advertising in the USA and NZ until we understand the trial data. Public safety is, and always will be, our main concern.
ENDS
Auckland University of Technology: Reading Helps Children Face A Difficult Future
PATHA: Puberty Blocker Evidence Brief Affirms Aotearoa’s Approach
Tataki Auckland Unlimited: Into Ocean & Ice - Unveiling Antarctica's Past And Present
Health Coalition Aotearoa: Urgent Action Needed To Address Aotearoa’s Shameful Household Food Insecurity
GPNZ: 2023/24 New Zealand Health Survey - One Quarter Of Kiwi Adults Unable To Access General Practice
University of Auckland: Screentime Rules Reduce Childhood Obesity Risk